TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06584695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Description: Patients will receive transversus abdominis plane block with an oblique subcostal approach in the supine position. The anesthesiologist will place the linear ultrasound transducer obliquely on the upper abdominal wall along the subcostal margin near the xiphisternum of the sternum in the midline of the abdomen. The anesthesiologist will direct a 22G, 80 mm needle toward the transversus abdominis fascia and inject 25 mL of 0.25% bupivacaine between the rectus abdominis and transversus abdominis muscles along the subcostal line.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: External Oblique Intercostal Plane Block
Description: Patients will receive external oblique intercostal block the patient will be in the supine position with their ipsilateral arm abducted, A linear ultrasound transducer will be placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib, with the orientation marker directed cranially. The skin will be sterilized, and the probe will be placed over the sixth rib medial to the anterior axillary line in a parasagittal orientation the in-plane technique with a 22G, 80 mm block needle will be used to inject 25 ml of 0.25% bupivacaine into the external oblique intercostal plane.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Patients will receive IV morphine 0.1mg/kg after induction of general anesthesia.~General anesthesia induction will be performed with fentanyl 1-2 μg/kg, propofol 2-3 mg/kg, and rocuronium 0.6 mg/kg and maintained with sevoflurane.
Study: NCT04982250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Formal peer PrEP referral + HIVST delivery
Description: After a brief training, young female PrEP users will be encouraged to refer up to 4 peers to PrEP using strategies gained from the training, PrEP educational materials (i.e., brochures), HIVST kits (2 kits/peer = 8 kits total), and Kenya MOH-style referral cards.
Study: NCT05101096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously (IV)
Study: NCT06262412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behaviour therapy (ICBT)
Description: The intervention is Internet-delivered and therapist-guided, involving both the adolescent and at least one caregiver. It consists of two separate sets of modules, one for the adolescent and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The first part includes psychoeducation about BDD and strategies to resolve possible ambivalence towards psychological treatment. The main goal of the treatment is to help the young person to stop avoiding anxiety-provoking situations (e.g., going to school or participating in social situations) by undertaking exposure tasks and to stop doing unhelpful repetitive behaviours and rituals (e.g., excessive mirror-checking, camouflaging), known as response prevention. Every module also contains homework tasks that are meant to be completed between modules and mainly consist of exposure and response prevention (ERP) tasks based on the young person's individual goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-delivered relaxation treatment (IRT)
Description: The intervention is Internet-delivered and therapist-guided, involving both the adolescent and at least one caregiver. It consists of two separate sets of modules, one for the adolescent and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The first part includes psychoeducation about BDD, how anxiety and stress are major contributors to BDD symptoms, and that targeting and reducing stress will have a beneficial impact on those symptoms. The main goal of the treatment is to teach the young person to relax in order to cope with anxiety and appearance concerns. The intervention mainly consists of a relaxation treatment and includes different relaxation skills such as deep breathing, progressive muscle relaxation, and imagery (cognitive relaxation). Every module also contains homework tasks that are meant to be completed between modules and mainly consist of relaxation tasks.
Study: NCT06551610

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Triage Tool
Description: Tool that uses patient characteristics to triage patients for an earlier procedure date vs the standard of care 12 week wait for procedure.
Study: NCT05849831

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound measurement of Optic nerve sheath diameter
Description: Ocular ultrasonography will be performed by single skilled examiner with patients placed in supine position with closed eyes. A layer of ultrasound gel will be applied over the closed upper eyelid and the liner high frequency probe 7 - 12 MHz of SonoSite M-Turbo ultrasound machine is placed on temporal area of eyelid with the hand holding it resting on forehead of patient. ONSD is measured 3mm behind the globe in the transverse plane perpendicular to the optic nerve. For each eye one measurement will be made and the reported ONSD corresponds to the mean of the two values obtained for each patient. An average ONSD greater than 5 mm is considered abnormal and elevated intracranial pressure should be suspected. all enrolled subjects will be eligible for ONSD measurements, SOFA score calculation, as well as GCS assessment on daily basis for up to 10 consecutive days, until ICU discharge or death.
Study: NCT06199570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Stress Management Program
Description: Participants will receive a 15-minute orientation session in-person or remotely to introduce the program and to receive the study materials, including the instructional sheet, small booklet, and study tablet that will be used to promote practice of stress management exercises and for completing study assessments. They will complete self-guided web modules with stress management activities/skills on tablet devices, and will rate the modules' acceptability and perceived helpfulness. After visiting each module, they will be asked to practice at least one skill daily. In a 1-week pre-scan call, they will be reminded about the skills, make a plan for using them, and troubleshoot questions about using the materials. Participants will attend scans and scan result appointments with their oncologist as usual. In a 1-week post-scan phone call, the stress management plan will be revisited for new concerns.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Enhanced usual care includes a resource list, tablet for study assessments, and reminder calls.
Study: NCT05363527

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Endotoxin

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06306599

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: S-Detect for Thyroid
Description: Deep learning based program on Samsung ultrasound machines designed to do real-time semi-automated analysis of thyroid nodules. The ultrasound operator freezes a transverse image of the patient's thyroid nodule and activates S-Detect. The operator selects the nodule on the screen, and the program automatically draws a region of interest. Then S-Detect gives a dichotomous diagnosis of either Possibly benign and Possibly malignant. In addition, it measures the nodule and characterises it with a lexicon based on EUTIRADS.
Study: NCT05160337

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Biomarker based IVD tests
Description: Biomarker based IVD tests
Study: NCT05668351

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SUPR-SABR treatment
Description: SUPR-SABR prescription dose to the PTV_4000 will be 8 Gy per fraction for five fractions. The prescription dose to PTV_3625 will be a minimum of 7.25 Gy per fraction for five fractions. SABR will be delivered 2-3 times a week, every other day. There will be a minimum of 40 hours between fractions and maximum of 128 hours between fractions.
Study: NCT05532150

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Bankart repair
Description: Participants in this group will undergo minimally invasive surgery to repair their shoulder with a technique called a Bankart repair.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Participants in this group will follow a specific physical therapy rehabilitation protocol
Study: NCT05640830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab, bevacizumab with paclitaxel (triple combination)
Description: Trastuzumab 4 mg/kg Day 1, 15 Bevacizumab 5 mg/kg Day 1, 15 Paclitaxel 80 mg/m2 Day 1, 8, 15 every 4 weeks
Study: NCT06356922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug [177Lu]Lu-PentixaTher
Description: Injection of \[177Lu\]Lu-PentixaTher
Study: NCT06594718

Intervention type: PROCEDURE
Intervention: Endoscopic diverticulotomy with Z-POEM
Description: Endoscopic diverticulotomy with Z-POEM

Intervention type: PROCEDURE
Intervention: Endoscopic diverticulotomy using a non-tunnelization technique
Description: Endoscopic diverticulotomy with diverticuloscope, Knife Septotomy, or Clutch Cutter
Study: NCT06590779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aminexil® active+ lotion
Description: Aminexil® active+ lotion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride 1mg
Description: Finasteride 1 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Finasteride 1mg
Description: Finasteride 1 mg
Study: NCT06599112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Densah Burs
Description: Series of drilling burs inserted in the osteotomy with special design that have a large negative rake angle flute, a cutting chisel edge and a tapered shank, so as they enter deeper into the osteotomy and they have a progressively increasing diameter that controls the expansion process. These burs are used with a standard surgical engine and can densify bone by rotating in the noncutting direction (counterclockwise at 800-1,200 rotations per minute) or drill bone by rotating in the cutting direction (clockwise at 800-1,200 rotations per minute) with an in and out movement together with copious saline irrigation and increasing bone plasticity and ability to expand under rate dependent stress.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteotomes
Description: The osteotomes kit are a series of tools that first designed by Summers in 1994. The concept was to maintain the existing bone by compressing trabecular bone laterally and apically with minimal trauma to improve the bone density. The condensed bone in this way will have to put in act a double repairing mechanism, from one side represented by the normal processes of osteointegration and on the other side from the processes of the reparation post fracture like that depends on BMU (bone modelling units) which create new spaces for the new vessels and afterwards filling all the gaps between the bone and the implant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional drilling
Description: The implant drilling kit provided by the manufacturer will be used for the implant placement, using the pilot drill followed by consequent drills according to the size of the osteotomy needed.
Study: NCT06593704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROSPERA-program
Description: The PROSPERA-program consists of the following components:~1. Health care provider training and education about U-Prevent and cardiovascular risk communication.~2. Risk stratification: proactive selection of cardiovascular patients through the PROSPERA-empanelment procedure - for the population with increased cardiovascular risk, prior to consultation.~3. Decision support tools: use of the Lifestylecheck and the U-Prevent clinical decision support tool to guide motivated shared decision making towards appropriate care matched to the care complexity of the patient - for the individual patient, during consultation.
Study: NCT05345444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRE & MRgRT
Description: Subjects will undergo Irreversible electroporation(IRE) followed by Magnetic resonance guided radiotherapy (MRgRT)
Study: NCT06589362

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous auricular vagus nerve stimulation
Description: In the active stimulation, two electrodes are placed in the cymba conchae of one of the ears, an area thought to be exclusively innervated by the auricular branch of the vagus nerve. In the sham stimulation, the electrodes are placed on the tail of helix, which is free of vagal innervation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous auricular vagus nerve stimulation
Description: In the active stimulation, two electrodes are placed in the cymba conchae of one of the ears, an area thought to be exclusively innervated by the auricular branch of the vagus nerve. In the sham stimulation, the electrodes are placed on the tail of helix, which is free of vagal innervation.
Study: NCT06601673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: The intervention consists of computer-based cognitive training in the areas of attention, processing speed, memory, emotional intelligence, reasoning and orientation. The training takes place under supervision for 120 minutes a day from the first to the fifth postoperative day.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Listen to audio book
Description: Here, an audio book is listened to for 2h daily for the first five postoperative days (or until discharge from hospital if earlier). The audio book is brought and set up by study staff.
Study: NCT06592092

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QH104 Cell injection
Description: Patients will first be pre-screened for B7H3 expression of tumor and exist Meningeal Metastases.
Study: NCT06590207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plasma rich with WNV neutralizing antibodies
Description: 200 ml plasma of the convalescents: produced in the blood bank, from the blood of Sheba workers who participated in the SPRI study (Helsinki 0196-23) and whose blood was found to have neutralizing antibodies to WNV above 1:524. The blood units from the volunteers who will donate will meet all the requirements of a normal blood donation and will only include men or women who were not pregnant, and the units will pass all the tests accepted at the blood bank before donation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study: NCT06593145

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FCTX-CL19-1 (Tarcidomgen Kimleucel)
Description: It will be administered only by Investigators during hospitalization. Each patient will receive one administration of IMP on Day 0:~* administration route - intravenous~* cell dose: 0,2 x 106 -2 x 106 CAR T cells per kilogram of patient body weight
Study: NCT06601491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Participants in the intervention group receive structured, pesonalised lifestyle, dietary and physical activity consultations. They undergo various assessments such as aortic stiffness measurement, blood pressure measurement, and complete several questionnaires (e.g., whole exome sequencing, IPAQ, handgrip strength, socio-demographic, clinical history, quality of life, smoking, alcohol consumption, sleep patterns, stress assessment).
Study: NCT06598969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide
Description: Evaluate the antileukemic activity of an total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide conditioning regimen for allogeneic hematopoietic stem cell transplantation
Study: NCT06586385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: disaster education
Description: The ADDIE Instructional Design Model will be used due to its suitability for adult education. General Disaster Awareness Training will be prepared according to the ADDIE instructional design model, which consists of five stages: analysis, design, development, implementation and evaluation. The trainings to be given will be given 1 week after the pre-test, 1 training per week, for a total of 3 trainings.
Study: NCT05607446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC3564 tablets
Description: TQC3564 tablets are CRTH2 antagonists.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: The intervention drug is placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC3564 tablets, montelukast sodium tablets
Description: The intervention drugs are TQC3564 tablets combined with montelukast sodium tablets. TQC3564 is a CRTH2 antagonist, montelukast sodium is Leukotriene receptor antagonist.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets, montelukast sodium tablets
Description: The intervention drugs are placebo combined with montelukast sodium tablets. Montelukast sodium is Leukotriene receptor antagonist.
Study: NCT06070766

Intervention type: DRUG
Intervention: Ketamine
Description: The use of ketamine in chronic conditions.

Intervention type: DRUG
Intervention: Ketamine
Description: The use of ketamine in chronic conditions.

Intervention type: DRUG
Intervention: Ketamine
Description: The use of ketamine in chronic conditions.

Intervention type: DRUG
Intervention: Ketamine
Description: The use of ketamine in chronic conditions.

Intervention type: DRUG
Intervention: Ketamine
Description: The use of ketamine in chronic conditions.

Intervention type: DRUG
Intervention: Ketamine
Description: The use of ketamine in chronic conditions.

Intervention type: DRUG
Intervention: Ketamine
Description: The use of ketamine in chronic conditions.

Intervention type: DRUG
Intervention: Ketamine
Description: The use of ketamine in chronic conditions.

Intervention type: DRUG
Intervention: Ketamine
Description: The use of ketamine in chronic conditions.

Intervention type: DRUG
Intervention: Ketamine
Description: The use of ketamine in chronic conditions.

Intervention type: DRUG
Intervention: Ketamine
Description: The use of ketamine in chronic conditions.

Intervention type: DRUG
Intervention: Ketamine
Description: The use of ketamine in chronic conditions.

Intervention type: DRUG
Intervention: Ketamine
Description: The use of ketamine in chronic conditions.
Study: NCT06594380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group using new oropharyngeal airway (experimental group)
Description: Before anesthesia induction, study participants in the experimental group received 5-6L/min oxygen for about 1min through an endoscopic bite oxygen supply device, and anesthesia induction was administered with propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. When participants achieved sufficient sedation (about BIS40), they were placed into the oropharyngeal airway through the endoscopic bite and began gastroscopy.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic bite group (control group)
Description: Prior to induction of anesthesia, control study participants inhaled 5 to 6L/min of oxygen through a nasal catheter for approximately 1 minute.Anesthesia was induced by propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. The endoscopic procedure began when the study participants reached sufficient sedation (about BIS40) and the ordinary endoscopic bite group reached sufficient sedation.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination.
Study: NCT06587581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Participants from the intervention group will receive the usual care over the 6-month intervention period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Participants from the intervention group will receive the usual care and an additional three text messages per week via WhatsApp over the 6-month intervention period
Study: NCT05393791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-specific adaptive therapy
Description: Patients will start taking abiraterone or enzalutamide (AA/ENZ) daily. PSA will be measured every month as well as radiological evaluation by CT-scan and bone scan. Treatment will be continued until PSA has dropped \>50%. The treatment will then be paused. Once the PSA has risen again above the pretreatment baseline, treatment will be re-initiated. AA/ENZ will be stopped again after the PSA declines \>50% from the baseline. This will be continued until criteria for treatment failure are met (death by any cause or at least 2 out of 3 of the following events while on treatment: radiographic progression on CT-scan and/or bone scan, PSA progression or clinical progression).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone acetate
Description: Use of abiraterone or enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Use of abiraterone or enzalutamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Use of abiraterone or enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Use of abiraterone or enzalutamide
Study: NCT06615206

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HG204
Description: The study will enroll up to 2 cohorts, evaluating a starting dose plus a higher or lower dose
Study: NCT06672406

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuterii
Description: Participants in the intervention group received probiotic Lactobacillus reuterii if they received enteral feeding \> 30 cc/kgBW. 5 drops of probiotics were given for 7 days in the breast milk or formula milk that did not contain probiotics